Taking Cordarone for short time not an option

By Michael Kahn

LONDON (Reuters) - Taking the Wyeth heart drug Cordarone for shorter periods of time did little to ease side effects and left patients with a higher risk of premature death than those taking it for long periods, Dutch researchers said on Tuesday.

Long-term use of the drug known generically as amiodarone is common for people with a type of irregular heart beat known as atrial fibrillation. But because it can cause allergies, liver, lung and other health problems, the researchers said they wanted to see if cutting time on the drug could help.

This was not the case, Isabelle Van Gelder of the University of Groningen in the Netherlands and colleagues reported in the Journal of the American Medical Association.

“This study shows that episodic amiodarone treatment — in contrast to our expectations — has no clinical advantage over continuous treatment because it did not lower morbidity in patients with persistent atrial fibrillation over 2 years of follow-up.”

Amiodarone is an ingredient in Wyeth’s Cordarone and is also sold generically. The medicine is used to control atrial fibrillation, a common but serious condition that causes the heart’s upper chambers to flutter.

It is important to treat the condition to prevent stroke. Many heart drugs can help, including those designed to slow the rapid heart rate associated with atrial fibrillation and blood thinners or anticoagulants that make a clot less likely to form.

In August U.S. health officials warned the public about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with amiodarone.

The Dutch trial included 209 men and women with irregular heartbeats assigned to receive either continuous or short-term treatment of two months. The researchers put those in the short-term group back on medication for a two-month burst if their irregular heartbeats returned.  Continued…


Related Posts:

By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - Sanofi-Aventis’s experimental drug Multaq significantly reduced the incidence of hospitalization and length of hospital stays in patients with atrial fibrillation, according to a new analysis of a previously reported study, researchers said on Tuesday. Multaq, known chemically as dronedarone, cut the total number of hospital days by

Full Post: Sanofi’s Multaq reduces hospitalization: study

By Will Dunham WASHINGTON (Reuters) - Women who consume more than two alcoholic drinks a day have a higher risk of getting the most common type of heart rhythm disturbance, which can raise the chances of having a stroke, researchers said on Tuesday. Previous research had shown that men who drink three or more alcoholic beverages daily

Full Post: Heart rhythm risk seen in women’s alcohol drinking

NEW YORK (Reuters Health) - Patients with atrial fibrillation — the most common type of heart arrhythmia — who suffer a stroke and are candidates for potentially life-saving anti-clotting therapy with warfarin are not prescribed the drug or are not prescribed enough of it, a study suggests. “These findings should encourage greater efforts to prescribe and

Full Post: Warfarin underused in some patients: study

By Amy Norton NEW YORK (Reuters Health) - Offering yet another reason to never start smoking, a new study finds that both current and former smokers run an elevated risk of the heart rhythm disorder atrial fibrillation. The condition, also known as AF, is the most common heart arrhythmia in the U.S., affecting about 2 million people.

Full Post: Smoking ups risk of common heart rhythm problem

NEW YORK (Reuters Health) - While the incidence of stroke as a complication of heart attack has decreased since the late 1990s, death during hospitalization in affected patients has not shown a corresponding decrease, new data suggest. “Although contemporary therapies may be reducing the risk of stroke in patients with (heart attack), more attention should be

Full Post: Cases of stroke complicating heart attack down

Site Navigation

Most Read



  • kinwrite.com@gmail.com